Press release
Macular telangiectasia Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | OXURION, Neurotech Pharmaceuticals
Macular telangiectasia Pipeline constitutes 4+ key companies continuously working towards developing 4+ Macular telangiectasia treatment therapies, analyzes DelveInsight.Macular telangiectasia Overview:
Macular Telangiectasia (MacTel) is a condition that impacts the macula, leading to a loss of central vision. It occurs due to issues with the tiny blood vessels around the fovea. There are two types of MacTel: Type 1 and Type 2. In Type 1 MacTel, blood vessels become dilated, leading to small aneurysms that cause swelling and damage to macular cells. This form typically affects one eye. Type 2 MacTel, the more common form, involves dilation and leakage of the capillaries around the fovea. This results in fluid buildup and swelling, impairing light reflection and causing progressive vision loss. As the damage progresses, new blood vessels may form, break, and leak, leading to scar tissue that further disrupts central vision. Type 2 MacTel typically affects both eyes and is most common in middle-aged adults.
Download our report @ https://www.delveinsight.com/report-store/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Macular telangiectasia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Macular telangiectasia Therapeutics Market.
Key Takeaways from the Macular telangiectasia Pipeline Report
DelveInsight's Macular telangiectasia pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Macular telangiectasia treatment.
In March 2025, the U.S. Food and Drug Administration (FDA) approved Encelto, a gene therapy implant developed by Neurotech Pharmaceuticals, for the treatment of MacTel. Encelto is the first FDA-approved therapy for this rare eye disease, marking a significant milestone in ophthalmology.
Key Macular telangiectasia companies such as OXURION, Neurotech Pharmaceuticals, and others are evaluating new drugs for Macular telangiectasia to improve the treatment landscape.
Promising Macular telangiectasia pipeline therapies in various stages of development include NT-501, THR 317, and others.
Macular telangiectasia Pipeline Analysis
The Macular telangiectasia pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Macular telangiectasia Market.
Categorizes Macular telangiectasia therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Macular telangiectasia drugs under development based on:
Stage of development
Macular telangiectasia Route of administration
Target receptor
Monotherapy vs. combination therapy
Macular telangiectasia Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Macular telangiectasia Licensing agreements
Funding and investment activities supporting future Macular telangiectasia market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Macular telangiectasia Emerging Drugs
NT-501: Neurotech Pharmaceuticals
NT-501 (Renexus) is an encapsulated cell therapy designed to treat Macular Telangiectasia (MacTel). Currently, it is being tested in a Phase 3, randomized, multi-center trial to assess the safety and efficacy of Renexus implants in individuals with Type 2 MacTel. NT-501 is an innovative cell-based drug delivery system, where human-derived cells are encapsulated in a semipermeable hollow fiber membrane device to release ciliary neurotrophic factor (CNTF). In July 2012, NT-501 received orphan drug status for MacTel type 2 from the FDA, and in February 2019, it was granted Fast Track designation for this indication.
THR 317: OXURION
THR-317 is an inhibitor of Placenta Growth Factor (PlGF) and is currently being assessed in a Phase II trial for the treatment of Idiopathic Macular Telangiectasia (MacTel) Type 1.
Macular telangiectasia Companies
There are about 4+ major companies working on therapies for Macular Telangiectasia (MacTel). Neurotech Pharmaceuticals is one of the companies with MacTel drug candidates in the most advanced stage, currently in Phase III.
DelveInsight's report covers around 4+ products under different phases of Macular telangiectasia clinical trials like
Macular telangiectasia Late stage Therapies (Phase III)
Macular telangiectasia Mid-stage Therapies (Phase II)
Macular telangiectasia Early-stage Therapies (Phase I)
Macular telangiectasia Pre-clinical and Macular telangiectasia Discovery stage Therapies
Macular telangiectasia Discontinued & Inactive Therapies
Macular telangiectasia pipeline report provides the Macular telangiectasia therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Macular telangiectasia Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Macular telangiectasia Therapies and Key Macular telangiectasia Companies: Macular telangiectasia Clinical Trials and recent advancements https://www.delveinsight.com/report-store/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Macular telangiectasia Pipeline Therapeutic Assessment
• Macular telangiectasia Assessment by Product Type
• Macular telangiectasia By Stage
• Macular telangiectasia Assessment by Route of Administration
• Macular telangiectasia Assessment by Molecule Type
Download Macular telangiectasia Sample report to know in detail about the Macular telangiectasia treatment market @ Macular telangiectasia Therapeutic Assessment https://www.delveinsight.com/sample-request/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Macular telangiectasia Current Treatment Patterns
4. Macular telangiectasia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Macular telangiectasia Late-Stage Products (Phase-III)
7. Macular telangiectasia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Macular telangiectasia Discontinued Products
13. Macular telangiectasia Product Profiles
14. Macular telangiectasia Key Companies
15. Macular telangiectasia Key Products
16. Dormant and Discontinued Products
17. Macular telangiectasia Unmet Needs
18. Macular telangiectasia Future Perspectives
19. Macular telangiectasia Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Macular telangiectasia Pipeline Reports Offerings: https://www.delveinsight.com/report-store/macular-telangiectasia-mactel-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Macular telangiectasia Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | OXURION, Neurotech Pharmaceuticals here
News-ID: 3989916 • Views: …
More Releases from DelveInsight Business Research LLP

Erectile Dysfunction Devices Market Outlook Report 2032 by DelveInsight Explorin …
DelveInsight's Erectile Dysfunction Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Erectile Dysfunction Devices Companies market shares, challenges, Erectile Dysfunction Devices Market Drivers, barriers, trends, and key market Erectile Dysfunction Devices companies in the market.
To read more about the latest highlights related to the Erectile Dysfunction Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/erectile-dysfunction-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key…

Structural Heart Devices Market Size Report 2032: DelveInsight Report on Demand …
DelveInsight's Structural Heart Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Structural Heart Devices Companies market shares, challenges, Structural Heart Devices Market Drivers, barriers, trends, and key market Structural Heart Devices companies in the market.
To read more about the latest highlights related to the Structural Heart Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/structural-heart-devices-market-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…

DelveInsight's Urolithiasis Management Devices Market 2032 Report Offering In-De …
DelveInsight's Urolithiasis Management Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Urolithiasis Management Devices Companies market shares, challenges, Urolithiasis Management Devices Market Drivers, barriers, trends, and key market Urolithiasis Management Devices companies in the market.
To read more about the latest highlights related to the Urolithiasis Management Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/urolithiasis-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…

Transradial Access Products Market Forecast Report 2032 by DelveInsight Featurin …
DelveInsight's Transradial Access Products Market Insights Report 2032 provides the current and forecast market analysis, individual leading Transradial Access Products Companies market shares, challenges, Transradial Access Products Market Drivers, barriers, trends, and key market Transradial Access Products companies in the market.
To read more about the latest highlights related to the Transradial Access Products Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/transradial-access-products-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…
More Releases for Macular
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound…
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro …
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be?
The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives in…
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.
Download White Paper: https://www.towardshealthcare.com/download-statistics/5375
Market Overview and Key Drivers
The macular…
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $12.84…
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, …
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview
Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis
Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The…
Global Macular Edema and Macular Degeneration Why This Topic is So Serious Nowad …
According to the report published by Allied Market Research, the Global Macular Edema And Macular Degeneration Market generated $8.30 billion in 2020, and is expected to reach $16.53 billion by 2030, exhibiting a CAGR of 7.3% from 2021 to 2030. The report offers an in-depth analysis of the market size, emerging and current trends, future estimations, and key players.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-sample/620
𝗖𝗢𝗩𝗜𝗗-𝟭𝟵 𝗜𝗺𝗽𝗮𝗰𝘁 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 (𝗣𝗿𝗲 & 𝗣𝗼𝘀𝘁)…